GSK shingles shot might trump Merck's Zostavax, analysts say

Though GlaxoSmithKline ($GSK) is still waiting on late-stage results from its shingles vaccine, HZ/su, Cowen & Co. analysts say the GSK shot may just be better than Merck's Zostavax. The deciding factor? An advantage for HZ/su in older people, the analysts said. More from FierceVaccines

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.